State Directory
Provider Records in Nevada
GLP1Search tracks 533 provider records across 15 Nevada cities. 9 records include explicit GLP-1, medication, or peptide treatment evidence; 524 are directory-only healthcare/provider records that need direct confirmation.
Provider Records
533
Cities
15
Treatment Evidence
9
Directory-Only
524
Market Snapshot
Where source-ready GLP-1 records are concentrated in Nevada
The Nevada source-ready local index is led by Las Vegas. Across the state, 98% of provider records include phone plus address or website coverage, 0% list public pricing, and 20% carry an upstream source/place signal.
Data Complete
98%
Pricing Visible
0%
Source Flagged
20%
Treatment-Specific Directories
Medication and peptide location pages for Nevada
These pages focus on high-intent treatment searches where the state has enough listing density to support a useful directory page.
Top Nevada cities for source-ready GLP-1 records
Featured provider records in Nevada
Novuskin Med SpaLas Vegas · Contact for PricingSemaglutide evidence, Tirzepatide evidenceSahara West Urgent Care & WellnessLas Vegas · Contact for PricingSemaglutide evidence, Tirzepatide evidenceHale Family Practice - SouthwestLas Vegas · Contact for PricingSemaglutide evidenceTrimBody M.D. SummerlinLas Vegas · Contact for PricingSemaglutide evidence, Tirzepatide evidenceLas Vegas BariatricsLas Vegas · Contact for PricingSemaglutide evidenceAlphagenics TRT & Weight LossLas Vegas · Contact for PricingTirzepatide evidenceBody Balance MedicalLas Vegas · Contact for PricingTirzepatide evidence
All covered cities in Nevada
Questions about provider records in Nevada
How many providers are listed?
GLP1Search lists 533 provider records across 15 cities in Nevada, including 9 treatment-evidence records and 524 directory-only records to verify.
Which cities have the most listings?
Las Vegas (394), Henderson (68), Reno (38), North Las Vegas (11), Sparks (5) currently have the highest listing density in Nevada.
What should patients compare?
Compare licensed clinical oversight, medication source, pharmacy type, public pricing, follow-up cadence, side-effect support, and whether the clinic documents semaglutide or tirzepatide availability.